Inhibiting LCN2-induced ferritinophagy may be a prospective therapeutic strategy for CKD-VC, but further studies are needed to demonstrate the clinical potential of this approach in patients with CKD-VC. This evidence concerns the gene LCN2 and chronic kidney disease.